Southwest OncologyGroup (SWOG)

 
Activated protocol list Closed protocol list

 

S1001 - A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-cell Lymphoma (DLBCL) - Closed (effective 6/19/2017)
S1206 - A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy with Carboplatin and Paclitaxel for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC), (NCI Study Number 8811) - Closed (effective 10/23/2017)
S1619 - A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed with Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma

SWOG S1206 Requirements

 

Institutions that were previously credentialed to participate in another protocol or have a question about your status for this protocol, please fill out the credentialing status inquiry form.

This study requires credentialing. The credentialing requirements are different depending on whether you are using a 3DCRT or IMRT technique. You can be credentialed for either 3DCRT or IMRT or both depending on your physician’s preference.

3D credentialing:

•  Must complete and submit to IROC Houston the 3D Conformal Benchmark

IMRT credentialing:

• Must complete and submit to IROC Houston the IMRT Facility Questionnaire.

•  Irradiate the IROC Houston's IMRT H&N phantom.2  Please fill in the phantom request form online.

OR

•  Complete and submit the IMRT Benchmark to IROC Houston

• If an institution is using IMRT with gating or tracking, the institution must irradiate IROC Houston’s lung phantom with motion platform. Please fill in the phantom request form online.

• If techniques are used to compensate for or limit respiratory motion the IROC Houston questionnaire on respiratory motion management must be submitted to IROC Houston.